<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=319805651697215&amp;ev=PageView&amp;noscript=1">

The Nexus Between Regenerative Medicine and Point of Care

Wed, Nov 04, 2015

At the recent Stem Cell Meeting on the Mesa, we had the opportunity to hear from more than 60 speakers and panelists covering a variety of topics related to regenerative medicine and its rapid maturation. The conference attracted more than 700 attendees, making it apparent that regenerative medicine is at the forefront of the next generation of therapies to treat disease.

In a recent research report1 that detailed global industry trends from 2013 to 2019 for the regenerative medicine market (bone and joint), the market is estimated to reach USD 6.5 billion in 2019, growing at a CAGR of 12.8 percent from 2013 to 2019. Another report,2 forecasts growth at a CAGR of 20.16 percent over the period from 2014 to 2019. And today, cancer immunotherapy drugs have captured nearly 50 percent of the overall oncology drugs market, generating about USD 41.0 billion in 2014 alone.

The accelerating growth in the market for regenerative medicines and advanced therapies is being fueled by support of the financial markets. In the second quarter 2015, total financings were USD 4.9 billion, up 129 percent from the same quarter in 2014.3

Cryoport is partnering with many of the most innovative companies involved in regenerative medicine and immunotherapies to minimize risk by bringing critical planning, science and certainty to their cold chain strategies, thus facilitating patient access to these critical therapies. In fact, our role in enabling these trials to proceed smoothly is being recognized by many of our partners as a critical element in their strategic planning to the point in which we are being asked to directly engage with investigator sites to support the process optimization of the distribution and use of these materials.

Cryoport is providing services for more than 50 active clinical trials (10 of which are Phase III regenerative therapy trials) involving thousands of patients and being conducted on nearly every continent — including North America, South America, Europe, Asia and Australia — all of which demonstrate the extraordinary technology, service and regulatory support that Cryoport provides its clients.

The clinical studies relate to an array of regenerative therapies, including CAR-T therapies. In total, Cryoport’s immunotherapy clients alone are expected to contribute as much $150 million of revenue for our company over the next five years or so.

These numbers tell part of the story of our safe, reliable frozen shipping solutions that enable end-to-end visibility and monitoring for mission-critical therapeutics. More importantly, we come to work each day dedicated to helping our clients bring life-saving, efficacious therapies to patients. 


 

1 Transparency Market Research
2 TechNavio Global Regenerative Medicine Market 2015-2019
3 The Alliance for Regenerative Medicine and Advanced Therapies Quarterly Data Report for Q2-2015